Table 1.
Baseline characteristics of the two cohorts.
| Ranolazine (n = 16) | No ranolazine (n = 16) | p value | |
|---|---|---|---|
| Age (years) | 69 ± 8 | 72 ± 8 | 0.268 |
| Female gender | 4 (25) | 4 (25) | — |
| BMI (kg/m2) | 30 ± 5 | 29 ± 4 | 0.224 |
| Dyslipidemia | 14 (88) | 12 (75) | 0.365 |
| Hypertension | 15 (94) | 15 (94) | — |
| Smoking | 10 (63) | 11 (69) | 0.709 |
| Diabetes on oral GLAs | 12 (75) | 8 (50) | 0.273 |
| Diabetes on insulin therapy | 3(19) | 5 (31) | 0.685 |
| Diabetes on oral GLAs and insulin | 1 (6) | 3 (19) | 0.597 |
| Previous PCI | 12 (75) | 11(69) | 0.694 |
| Previous CABG | 3 (19) | 3 (19) | — |
| LVEF (%) | 56 ± 7 | 50 ± 9 | 0.089 |
| Angina (CCS III-IV) | 5 (31) | 1 (6) | 0.172 |
| Multivessel disease | 12 (75) | 11 (69) | 0.694 |
| Haemoglobin (g/dl) | 13.6 ± 1.2 | 13.0 ± 1.9 | 0.375 |
| Creatinine (mg/dl) | 0.9 ± 0.2 | 1.1 ± 0.3 | 0.086 |
| GFR (ml/min/1.73 m2) | 82.0 ± 26.5 | 73.6 ± 24.3 | 0.364 |
| Statins | 14 (88) | 15 (94) | 0.544 |
| Beta-blockers | 12 (75) | 12 (75) | — |
| ACE-inhibitors/ARBs | 13 (81) | 16 (100) | — |
| Nitrates | 10(63) | 11 (69) | 0.709 |
| Calcium-channel blockers | 8 (50) | 11 (69) | 0.472 |
| Biguanides | 11 (69) | 9 (56) | 0.716 |
| Sulfonylureas | 5 (31) | 1 (6) | 0.172 |
| Meglitinides | 3(19) | 2 (13) | 1 |
| TZD | 0 | 0 | — |
| DPP-4 inhibitors | 3 (19) | 2 (13) | 1 |
| SGLT-2 inhibitors | 0 | 1 (6) | — |
| GLP-1 agonists | 0 | 0 | — |
| Insulin | 4 (25) | 8 (50) | 0.273 |
Values are mean ± SD or n (%). ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blockers; BMI: body mass index; CABG: coronary artery bypass surgery; CCS: Canadian Cardiovascular Society; DPP: 4-dipeptidyl-peptidase 4; GLA: glucose-lowering agents; GLP-1: glucagon-like peptide 1; GFR: glomerular filtration rate; LVEF: left ventricular ejection fraction; PCI: percutaneous coronary intervention; SGLT2: sodium-glucose transporter 2; TZD: thiazolidinediones.